论文部分内容阅读
目的观察低分子肝素治疗在慢性阻塞性肺疾病急性加重期(AECOPD)的作用及疗效。方法将90例AE-COPD患者随机分为治疗组(A组)48例和对照组(B组)42例。对照组予以常规治疗,治疗组在常规治疗基础上加用低分子肝素抗凝治疗,7d为一疗程。结果治疗组较对照组动脉血氧分压和二氧化碳分压明显好转,D-二聚体明显下降(P﹤0.05),呼吸困难改善明显,住院时间缩短,总有效率(显效+有效)(93.8%)高于对照组(88.1%),无严重不良反应发生。结论低分子肝素抗凝治疗能改善AECOPD患者血液高凝状态,利于病情改善。
Objective To observe the effect and therapeutic effect of low molecular weight heparin on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Ninety patients with AE-COPD were randomly divided into treatment group (A group) 48 cases and control group (B group) 42 cases. The control group was given routine treatment. The treatment group was given low molecular weight heparin anticoagulation therapy on the basis of routine treatment, and 7 days was a course of treatment. Results Compared with the control group, arterial partial pressure of oxygen and partial pressure of carbon dioxide improved significantly in the treatment group, D-dimer decreased significantly (P <0.05), dyspnea improved obviously, hospitalization time shortened, total effective rate (markedly effective + effective) %) Higher than the control group (88.1%), no serious adverse reactions occurred. Conclusion Low molecular weight heparin anticoagulant therapy can improve blood hypercoagulability in patients with AECOPD, which will benefit the patients’ condition.